8-K: Lilly Q2 2025 Revenue Soars 38%, Guidance Raised

Eli Lilly and Company reported a 38% increase in second-quarter 2025 revenue to $15.56 billion, driven by strong sales of Zepbound and Mounjaro, leading to raised full-year guidance.

Summary

• Worldwide revenue for Q2 2025 was $15.56 billion, an increase of 38% compared to Q2 2024, driven by a 42% increase in volume, partially offset by a 6% decrease due to lower realized prices.
• Key Products revenue grew to $10.40 billion in Q2 2025, led by Zepbound and Mounjaro.
• Reported Earnings Per Share (EPS) for Q2 2025 increased 92% to $6.29, while non-GAAP EPS increased 61% to $6.31.
• Full-year 2025 revenue guidance was raised to a range of $60.0 billion to $62.0 billion, up from the prior range of $58.0 billion to $61.0 billion.
• Full-year 2025 reported EPS guidance was raised to $20.85 to $22.10, and non-GAAP EPS guidance was raised to $21.75 to $23.00.
• Pipeline progress included positive Phase 3 results for orforglipron in obesity, Mounjaro SURPASS CVOT for type 2 diabetes and heart disease, and Jaypirca head-to-head versus Imbruvica in CLL/SLL.
• Business development activity included the completed acquisitions of SiteOne Therapeutics, Inc. and Verve Therapeutics, Inc.

Sentiment

Score: 9

Explanation: The filing indicates exceptionally strong financial performance with significant revenue and EPS growth, driven by blockbuster drugs. The company also raised its full-year guidance and reported multiple positive clinical trial outcomes for key pipeline assets, including head-to-head wins against competitors. While there's a slight negative from lower realized prices and a tax rate increase, the overall picture is overwhelmingly positive, demonstrating robust growth and future potential.

Positives

• Strong revenue growth: 38% increase to $15.56 billion in Q2 2025, driven by robust volume growth.
• Exceptional sales performance of key products: Zepbound revenue increased 172% to $3.38 billion, and Mounjaro revenue increased 68% to $5.20 billion.
• Increased full-year 2025 revenue guidance by $1.5 billion at the midpoint, now projected between $60.0 billion and $62.0 billion.
• Raised full-year 2025 reported EPS guidance to $20.85-$22.10 and non-GAAP EPS guidance to $21.75-$23.00.
• Positive Phase 3 clinical trial results for orforglipron in obesity, showing weight loss of up to an average of 27.3 lbs.
• Mounjaro demonstrated cardiovascular protection in a landmark head-to-head trial for patients with type 2 diabetes and heart disease.
• Jaypirca met its primary endpoint in a head-to-head Phase 3 trial versus Imbruvica in CLL/SLL.
• Donanemab received a positive opinion from the CHMP and FDA approval for an updated label in early symptomatic Alzheimer's disease, along with marketing authorization in Australia.
• Expanded manufacturing capacity to meet increasing demand for products.
• Strategic acquisitions of SiteOne Therapeutics and Verve Therapeutics are expected to advance the pain and cardiovascular pipelines, respectively.

Negatives

• Lower realized prices resulted in a 6% decrease globally and an 8% decrease in the U.S. for Q2 2025, primarily impacting Zepbound and Mounjaro.
• The estimated effective tax rate for 2025 increased from approximately 17% to 19% on a reported basis due to recently enacted U.S. tax legislation.

Risks

• Significant costs and uncertainties inherent in the pharmaceutical research and development process, including the timing and process of obtaining regulatory approvals.
• The impact and uncertain outcome of acquisitions and business development transactions, along with related costs.
• Intense competition affecting the company's products, pipeline, or the broader industry.
• Uncertainty regarding the market uptake of newly launched products and indications.
• Continued pricing pressures and the impact of actions by governmental and private entities affecting pricing, reimbursement, and patient access to pharmaceuticals.
• Potential safety or efficacy concerns associated with the company's products or competitive products.
• Dependence on a relatively small number of products or product classes for a significant percentage of total revenue and a consolidated supply chain.
• The expiration of intellectual property protection for certain products and increased competition from generic and biosimilar products.
• Challenges in protecting and enforcing patents and other intellectual property rights, as well as changes in patent law or regulations.
• Risks related to information technology system inadequacies, security breaches, or operating failures, including unauthorized access or compromise of confidential data.
• Issues with product supply and regulatory approvals stemming from manufacturing difficulties, disruptions, or shortages.
• Reliance on third-party relationships and outsourcing arrangements.
• The use of artificial intelligence or other emerging technologies, which may exacerbate competitive, regulatory, litigation, and cybersecurity risks.
• The impact of global macroeconomic conditions, including uneven economic growth, trade disputes, international tension, and conflicts.
• Fluctuations in foreign currency exchange rates, changes in interest rates, and inflation or deflation.
• Potential for significant and sudden declines or volatility in the trading price of the company's common stock and market capitalization.
• Litigation, investigations, or other similar proceedings involving past, current, or future products or activities.
• Changes in tax law and regulations, tax rates, or events that differ from tax position assumptions.
• Regulatory changes and developments, as well as regulatory oversight and actions regarding operations and products.
• Regulatory compliance problems or government investigations.
• Risks from the proliferation of counterfeit, misbranded, adulterated, or illegally compounded products.
• Actual or perceived deviation from environmental-, social-, or governance-related requirements or expectations.
• Potential for asset impairments and restructuring charges.
• Changes in accounting and reporting standards.

Future Outlook

Eli Lilly raised its full-year 2025 revenue guidance to a range of $60.0 billion to $62.0 billion, up from $58.0 billion to $61.0 billion, driven by strong underlying business performance and favorable foreign exchange rates. Reported EPS guidance was increased to $20.85 to $22.10, and non-GAAP EPS guidance to $21.75 to $23.00. The company anticipates continued investments in its early and late-stage portfolio and promotional efforts for ongoing and future launches, alongside expanding manufacturing capacity.

Management Comments

• "Lilly delivered another quarter of strong performance, achieving 38% year-over-year revenue growth driven by robust sales of Zepbound and Mounjaro and sustained momentum across our key medicines."
• "Our pipeline continued to advance, highlighted by positive study results in oncology and cardiometabolic health—including Mounjaro’s demonstrated cardio-protective effects in patients with type 2 diabetes and heart disease and strong data for our oral incretin, orforglipron, in obesity."
• "We also expanded manufacturing capacity to meet increasing demand and invested in key R&D initiatives to support our long-term growth."

Industry Context

Eli Lilly's strong performance, particularly in cardiometabolic health with Zepbound and Mounjaro, positions it as a leader in the rapidly expanding obesity and diabetes markets. The positive clinical trial results for orforglipron and Mounjaro's cardiovascular benefits reinforce its competitive edge. The company's advancements in Alzheimer's and oncology, including Jaypirca's head-to-head success, demonstrate a diversified and robust pipeline, aligning with broader industry trends focusing on high-unmet-need therapeutic areas and next-generation treatments.

Comparison to Industry Standards

• Mounjaro (tirzepatide) demonstrated cardiovascular protection in a landmark head-to-head trial, reinforcing its benefit in patients with type 2 diabetes and heart disease.
• Jaypirca (pirtobrutinib), the first and only approved non-covalent (reversible) BTK inhibitor, met its primary endpoint in a head-to-head Phase 3 trial versus Imbruvica (ibrutinib) in CLL/SLL, indicating superior or non-inferior efficacy.
• Zepbound (tirzepatide) showed superior weight loss over Wegovy (semaglutide) in complete SURMOUNT-5 results published in The New England Journal of Medicine, positioning it favorably against a key competitor in the obesity market.

Management Changes

Legal Proceedings

• In Q2 2024, there was a charge of $435.0 million related to litigation. No new litigation details for Q2 2025 were provided in this filing.

Stakeholder Impact

• Shareholders: Positive impact due to strong financial performance, increased revenue and EPS guidance, robust product sales (Zepbound, Mounjaro), and promising pipeline developments, which could lead to increased share value.
• Customers/Patients: Positive impact from new product approvals (e.g., updated Kisunla label) and positive clinical trial results for treatments in obesity, diabetes, Alzheimer's, and oncology, potentially offering more effective or new treatment options.
• Employees: Positive impact from company growth, expansion of manufacturing capacity, and continued investment in R&D, suggesting job stability and potential growth opportunities.
• Creditors: Strong financial health and increased revenue/profitability enhance the company's ability to meet its financial obligations.

Next Steps

• Continued investments in the company's early and late-stage R&D portfolio.
• Promotional efforts supporting ongoing and future product launches.
• Expansion of manufacturing capacity to meet increasing demand.
• Integration of acquired companies (SiteOne Therapeutics, Verve Therapeutics) to advance the pipeline.
• Potential future announcements regarding clinical trial results and regulatory approvals for pipeline assets.

Key Dates

Recommendation

Eli Lilly's Q2 2025 results significantly exceeded expectations, demonstrating exceptional revenue growth driven by the strong performance of Zepbound and Mounjaro. The substantial increase in full-year guidance for both revenue and EPS signals robust confidence in continued growth. Furthermore, the positive clinical trial outcomes for key pipeline assets, including head-to-head wins against competitors and advancements in high-demand therapeutic areas like obesity and Alzheimer's, de-risk future growth prospects. Despite minor headwinds from lower realized prices and a tax rate adjustment, the overall trajectory and strategic positioning warrant a 'strong buy' recommendation for long-term investors.

Keywords

Eli Lilly, LLY, Pharmaceuticals, Biotechnology, Drug Development, Obesity, Diabetes, Alzheimer's, Oncology, Zepbound, Mounjaro, Verzenio, Donanemab, Orforglipron, Jaypirca, Financial Results, Earnings, Guidance, Q2 2025, SEC Filing, 8-K